Open access
Open access
Powered by Google Translator Translator

Preliminary findings from a randomized trial showed promising results from dual PD-1 and HER2 blockade in HER2-positive gastric cancer.

14 Jan, 2022 | 08:03h | UTC

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer – Nature

Commentary: KEYNOTE-811: Pembrolizumab combination as a potentially transformative treatment for HER2-positive gastric cancer – Vall d’Hebron University Hospital

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.